Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

被引：24

作者：

Wethington, Stephanie L.

Shah, Payal D.

Martin, Lainie P.

Tanyi, Janos Laszlo

Latif, Nawar A.

Morgan, Mark Aloysuis

Torigian, Drew A.

Pagan, Cheyenne

Rodriguez, Diego

Domchek, Susan M.

Drapkin, Ronny

Shih, Le-Ming

Smith, Simon

Dean, Emma

Armstrong, Deborah Kay

Gaillard, Stephanie

Simpkins, Fiona

机构：

[1] Johns Hopkins Univ, Baltimore, MD USA

[2] Univ Penn, Philadelphia, PA 19104 USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[5] Hosp Univ Penn, Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA

[6] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] AstraZeneca, Cambridge, England

[9] Univ Manchester, Manchester, Lancs, England

[10] Christie NHS Fdn Trust, Manchester, Lancs, England

[11] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[12] Johns Hopkins Sch Med, Baltimore, MD USA

[13] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.5516

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5516

引用

页数：3